Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGAH.L Regulatory News (GAH)

  • There is currently no data for GAH

Trading Update

31 Mar 2016 07:00

RNS Number : 6048T
Gable Holdings Inc
31 March 2016
 

31 March, 2016

Gable Holdings Inc.

Trading Update

Further to the statement made on 21 December 2015, Gable Holdings Inc. ("Gable" or the "Company") today provides a trading update for the 12 month period ended 31 December 2015.

 

Summary

§ Gross Written Premiums of over £100m, representing a 25% increase over the prior period

§ High retention rates and new referrals continue to drive strong growth in underlying business across all European markets

§ Over 40% increase in cash and liquid investment balances to £60m

§ Pre-tax loss for the group expected to be between £7 million and £8 million after taking into account:

o Previously announced £7.5 million provision to eliminate the remaining balance of the pre-2012 historical reserving gap;

o The cost of the Quota Share agreement as announced in December 2015; and

o Provisions for claims arising from the significant floods experienced in the UK and Europe in December 2015, the impact of which is limited to between £2 million and £3 million through reinsurance arrangements 

§ The Company's Loan Note Instrument is closed with immediate effect and no further Loan Notes will be issued. The funding provided by the instrument ensured compliance with current solvency requirements under the transitional provisions of Solvency II, utilised by the Company and many other insurers across Europe. The transitional provisions set out in European Directives (and encompassed within Liechtenstein Law) give an insurer until 31 December 2017 to fully comply with Solvency II capital requirements

 

UK and European storms

In common with many other insurers in this market, the Company is experiencing claims arising from the storms and floods experienced in the UK and Europe at the end of 2015. We expect that reinsurance arrangements will limit the financial impact to between £2 million and £3 million.

 

Convertible Loan Note Instrument

On 21 December 2015 Gable announced the issue of a Convertible Loan Note Instrument with a term of three years under which Loan Notes may be issued up to a maximum aggregate value of £10 million. The Company issued Loan Notes amounting to £3.96m during 2015 and has no intention to issue any further Notes under the Instrument. 

 

Current Trading and Outlook

§ Momentum of high quality new business opportunities has continued into 2016

§ We continue to review our underwriting portfolio to ensure focus on profitability, core customers and strategic classes of business and have initiated a programme to review business which does not meet our underwriting criteria

§ We remain focused on delivering profitable underlying insurance results

 

Commenting, William Dewsall, Chief Executive of Gable, said:

"Gable produced another year of growth in the underlying business with a strong core underwriting performance which was achieved in challenging markets. The overall performance was impacted only at the year-end by the severe December storms and floods, and we were once again quick to respond to our customers' requirements in getting many businesses back in action following the storms, whilst Gable was also well protected through its reinsurance arrangements, limiting the ultimate financial impact. We remain focussed on delivering underwriting profits with a strong and growing cash position which has continued to increase by over 40% on 2014.

 

"I should like to thank those who supported Gable's December funding round which has ensured compliance under the transitional provisions of Solvency II.

"We are encouraged by the continued momentum in high quality new business that we have seen during the first quarter which give us confidence concerning the levels of profitable business that we can achieve during the 2016.

"We also note with interest that Allianz Risk Transfer AG based in Switzerland has recently announced that it intends to relocate its European headquarters to Liechtenstein at the end of 2016 pending regulatory approvals. We are delighted that it both endorses the excellent regulatory credentials of the FMA in Liechtenstein and brings another major European non-life insurance company into the country."

ENDS

Enquiries:

Gable Holdings Inc.

William Dewsall, Chief Executive

Michael Hirschfield, Group Finance Director

John Bick, Investor Relations

 

Tel: +44(0) 20 7337 7460

Zeus Capital Limited

Nicholas How, Corporate Finance

Adam Pollock, Corporate Broking

Tel: +44(0) 20 3829 5000

Haggie Partners LLP

Peter Rigby

Ned Ellison

Rob Tuttlebee

Tel : +44(0) 20 7562 4444

 

About Gable Holdings Inc.

 

Gable is a European non-life insurance company underwriting a comprehensive range of specialist policies for the commercial sectors in the UK, Denmark, France, Germany, Italy, Norway, Spain and Sweden. Gable benefits from a low-cost online underwriting platform and the Company has continued to successfully grow its business geographically whilst simultaneously exploiting a range of niche insurance segments which exist across the EU, which is delivered through the EU passporting mechanism. Gable Holdings Inc. is quoted on the London Stock Exchange's AIM market. For further information please visit www.gableholdings.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTAKKDPPBKDPNN
Date   Source Headline
11th Aug 20147:00 amRNSGen Re signs as Reinsurance Partner
17th Jul 20147:00 amRNSNew Business - UK
27th Jun 201410:18 amRNSGrant of Options
25th Jun 20142:03 pmRNSResult of AGM
25th Jun 20147:00 amRNSAGM Statement
19th Jun 20142:25 pmRNSIssue of Equity + TVR
3rd Jun 201411:01 amRNSDirector/PDMR Shareholding
2nd Jun 20144:27 pmRNSAnnual Financial Report
19th May 20147:00 amRNSFinal Results
12th May 20147:00 amRNSNotice of Results
12th May 20147:00 amRNSDirectorate Change
1st May 20147:00 amRNSRegulatory Approval - UK Motor Classes
1st Apr 20147:00 amRNSIssue of Equity + Total Voting Rights
13th Mar 20147:00 amRNSNew UK Specialist Commercial Bonds Programme
5th Mar 20147:00 amRNSNew Business and Notice of Results
18th Feb 20147:00 amRNSIssue of Equity and TVR
13th Feb 20148:49 amRNSHolding(s) in Company
27th Jan 20144:19 pmRNSHolding(s) in Company
24th Jan 20147:00 amRNSIssue of Equity + Total Voting Rights
22nd Jan 20145:23 pmRNSDirector/PDMR Shareholding
22nd Jan 20147:00 amRNSAon Agreement
11th Dec 20133:47 pmRNSHolding(s) in Company
4th Dec 20137:00 amRNSEuropean Approval - 3 New Insurance Classes
26th Nov 20133:29 pmRNSIssue of Equity + TVR
20th Nov 20137:00 amRNSNew product launch - Italy
5th Nov 20132:56 pmRNSHolding(s) in Company
5th Nov 20132:46 pmRNSHolding(s) in Company
5th Nov 20132:41 pmRNSTotal Voting Rights
5th Nov 20137:00 amRNSHolding(s) in Company
1st Nov 20133:34 pmRNSHolding(s) in Company
30th Oct 201312:27 pmRNSResult of Equity Issue
30th Oct 20137:00 amRNSPlacing + Subscription for £10.7m
24th Sep 20137:00 amRNSDirectorate Change and Netherlands First Product
6th Sep 20137:00 amRNSHalf Yearly Report
2nd Aug 201311:22 amRNSDirector/PDMR Shareholding
30th Jul 20131:23 pmRNSResult of AGM
30th Jul 20137:00 amRNSAGM Statement
2nd Jul 20137:00 amRNSDirector/PDMR Shareholding
1st Jul 20137:00 amRNSAnnual Financial Report
28th Jun 20133:44 pmRNSFinal Results
25th Jun 20134:14 pmRNSNotice of Results
9th May 20137:00 amRNSFirst Product Launch in Italy
15th Mar 201312:21 pmRNSDirector/PDMR Shareholding
4th Mar 20137:15 amRNSChange of Registered Office
1st Feb 201311:42 amRNSHolding in Company + Director PDMR
13th Dec 20127:00 amRNSDirector/PDMR Shareholding - Replacement
11th Dec 20127:00 amRNSDirector/PDMR Shareholding
5th Dec 201211:17 amRNS£70m 5-year Towergate agreement
27th Nov 20127:00 amRNSDenmark First Product and New ATE Programme
28th Sep 20127:00 amRNSHalf Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.